Lp(a) Lowering Study of Pelacarsen (TQJ230) in Patients in the US With Elevated Lp(a) and Recent ACS (STEMI/NSTEMI) - Lp(a)FRONTIERS PEARL
Clinical trial NCT07625306 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07625306
- Sponsor
- Novartis Pharmaceuticals
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-08-31
- Primary completion
- 2028-12-07
- Enrollment
- 240
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.